690 related articles for article (PubMed ID: 29455669)
1. EGFR-TKIs resistance via EGFR-independent signaling pathways.
Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
Yu HA; Riely GJ; Lovly CM
Clin Cancer Res; 2014 Dec; 20(23):5898-907. PubMed ID: 25303979
[TBL] [Abstract][Full Text] [Related]
3. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
4. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Liao BC; Lin CC; Yang JC
Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
[TBL] [Abstract][Full Text] [Related]
5. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.
Niederst MJ; Engelman JA
Sci Signal; 2013 Sep; 6(294):re6. PubMed ID: 24065147
[TBL] [Abstract][Full Text] [Related]
6. ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.
Jaiswal BS; Durinck S; Stawiski EW; Yin J; Wang W; Lin E; Moffat J; Martin SE; Modrusan Z; Seshagiri S
Clin Cancer Res; 2018 Aug; 24(16):4044-4055. PubMed ID: 29760222
[No Abstract] [Full Text] [Related]
7. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
8. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
9. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
[TBL] [Abstract][Full Text] [Related]
10. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.
Suda K; Mizuuchi H; Murakami I; Uramoto H; Tanaka F; Sato K; Takemoto T; Iwasaki T; Sekido Y; Yatabe Y; Mitsudomi T
Lung Cancer; 2014 Aug; 85(2):147-51. PubMed ID: 24939008
[TBL] [Abstract][Full Text] [Related]
11. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
[TBL] [Abstract][Full Text] [Related]
13. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
14. Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation.
Kim N; Cho A; Watanabe H; Choi YL; Aziz M; Kassner M; Joung JG; Park AK; Francis JM; Bae JS; Ahn SM; Kim KM; Park JO; Park WY; Ahn MJ; Park K; Koo J; Yin HH; Cho J
Oncotarget; 2016 Mar; 7(12):13797-809. PubMed ID: 26883194
[TBL] [Abstract][Full Text] [Related]
15. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
[TBL] [Abstract][Full Text] [Related]
16. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation.
Osoegawa A; Hashimoto T; Takumi Y; Abe M; Yamada T; Kobayashi R; Miyawaki M; Takeuchi H; Okamoto T; Sugio K
Invest New Drugs; 2018 Dec; 36(6):999-1005. PubMed ID: 29594878
[TBL] [Abstract][Full Text] [Related]
18. The Expression Pattern of p120-Catenin is Associated With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Liu Y; Wang S; Dong QZ; Liu N; Han Y; Zhang XP; Fan CF; Wang EH
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):64-70. PubMed ID: 27299185
[TBL] [Abstract][Full Text] [Related]
19. [Molecular mechanisms of targeted drug resistance in lung cancer and its therapeutic strategy].
Yano S
Nihon Rinsho; 2015 Aug; 73(8):1378-83. PubMed ID: 26281693
[TBL] [Abstract][Full Text] [Related]
20. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
